Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 2;9(3):00665-2022.
doi: 10.1183/23120541.00665-2022. eCollection 2023 Jul.

Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma

Nora Drick  1   2 , Lina Brinkmann  1 , Jan Fuge  1   2 , Tobias Welte  1   2 , Hendrik Suhling  1   2
Affiliations

Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma

Nora Drick et al. ERJ Open Res. .

Abstract

This retrospective study shows that treatment with anti-eosinophilic antibodies in patients with severe eosinophilic asthma is associated with an increase in work productivity and a decrease in missed days at work https://bit.ly/3IIPppR.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: N. Drick reports speaker fees for AstraZeneca. H. Suhling reports speaker fees for AstraZeneca, GlaxoSmithKline (GSK) and Novartis. J. Fuge reports speaker fees for AstraZeneca. T. Welte reports personal fees from AstraZeneca, GSK and Sanofi Aventis, and his institution has received research grants from the German Ministry of Research and Education. L. Brinkmann has no relevant conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Change of the WPAI-VAS and missed days at work from baseline (prior to treatment) to follow-up (control under anti-IL-5/anti-IL-5Rα treatment). WPAI: work productivity and activity impairment; VAS: visual analogue scale; IL: interleukin.
See this image and copyright information in PMC

References

    1. Hyland ME, Whalley B, Jones RC, et al. . A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res 2015; 24: 631–639. doi:10.1007/s11136-014-0801-x - DOI - PubMed
    1. Braman SS. The global burden of asthma. Chest 2006; 130: Suppl. 1, 4S–12S. doi:10.1378/chest.130.1_suppl.4S - DOI - PubMed
    1. Bahadori K, Doyle-Waters MM, Marra C, et al. . Economic burden of asthma: a systematic review. BMC Pulm Med 2009; 9: 24. doi:10.1186/1471-2466-9-24 - DOI - PMC - PubMed
    1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2022. Available from: http://ginasthma.org/
    1. Chen H, Blanc PD, Hayden ML, et al. . Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health 2008; 11: 231–239. doi:10.1111/j.1524-4733.2007.00229.x - DOI - PubMed